Targeting CD38 for acute leukemia
Authors:
Open Access
- 12 October 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 1007783
Abstract
Acute leukemia (AL) is a hematological malignancy, and the prognosis of most AL patients hasn’t improved significantly, particularly for relapsed or refractory (R/R) AL. Therefore, new treatments for R/R adult acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are urgently necessary. Novel developments have been made in AL treatment, including target and immune therapies. CD38 is one of the targets due to its high expression in many hematological malignancies, including multiple myeloma, ALL and a subset of AML. Consequently, targeting CD38 therapies, including CD38 monoclonal antibodies (mAbs), bispecific antibodies, and CAR-T cell therapy, exhibit promising efficacy in treating multiple myeloma without significant toxicity and are being explored in other hematological malignancies and nonhematological diseases. Herein, this review focuses on targeting CD38 therapies in ALL and AML, which demonstrate sound antileukemic effects in acute leukemia and are expected to become effective treatment methods.Keywords
This publication has 76 references indexed in Scilit:
- Tetrameric Interaction of the Ectoenzyme CD38 on the Cell Surface Enables Its Catalytic and Raft-Association ActivitiesStructure, 2012
- Anthracycline Dose Intensification in Acute Myeloid LeukemiaNew England Journal of Medicine, 2009
- Retinoic acid‐induced CD38 expression in HL‐60 myeloblastic leukemia cells regulates cell differentiation or viability depending on expression levelsJournal of Cellular Biochemistry, 2005
- Immunophenotypic Profile of Lymphoplasmacytic Lymphoma/Waldenström MacroglobulinemiaAmerican Journal of Clinical Pathology, 2005
- Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple MyelomaAmerican Journal of Clinical Pathology, 2004
- Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple MyelomaAmerican Journal of Clinical Pathology, 2004
- Molecular Mechanism of Human CD38 Gene Expression by Retinoic AcidJournal of Biological Chemistry, 1998
- Expression of CD38 Gene, but Not of Mitochondrial Glycerol-3-Phosphate Dehydrogenase Gene, Is Impaired in Pancreatic Islets of GK RatsBiochemical and Biophysical Research Communications, 1995
- A Single Protein Immunologically Identified as CD38 Displays NAD+ Glycohydrolase, ADP-Ribosyl Cyclase and Cyclic ADP-Ribose Hydrolase Activities at the Outer Surface of Human ErythrocytesBiochemical and Biophysical Research Communications, 1993
- Chromosome assignment of monoclonal antibody‐defined determinants on human leukemic cellsEuropean Journal of Immunology, 1983